Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lina Han

Showing results (171-180 of 174) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 174 results.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Nature Medicine|June 13, 2018
An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityJennifer R Molina, Yuting Sun, Marina Protopopova, et al.
Pageof 18

Showing results (171-180 of 174) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 174 results.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Nature Medicine|June 13, 2018
An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityJennifer R Molina, Yuting Sun, Marina Protopopova, et al.
Pageof 18